A Study of Three Doses of TCH346 in Patients With Early Parkinson's Disease to Evaluate Safety and Efficacy

Inclusion Criteria: * Male or female ,aged 30-80 years * Clinical diagnosis of early stage idiopathic Parkinson's disease * Experiencing two of the three following signs; bradykinesia, rigidity, and tremor * Not currently taking any antiparkinson medication Exclusion Criteria: * A history of alcohol or drug abuse in the past year * A diagnosis psychiatric illness * Patients who currently are taking MAO inhibitors within 30 days of entering the study * Patients who are hypersensitive to selegiline, MAO-B inhibitors, or tricyclic antidepressants Additional inclusion/exclusion criteria may apply